Genomic Health, Inc. (GHDX) Misses Q4 EPS by 2c, Offers FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Price: $63.44 --0%
Financial Fact:
Product revenues: 244.92M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Product revenues: 244.92M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Genomic Health, Inc. (NASDAQ: GHDX) reported Q4 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $53.4 million versus the consensus estimate of $53.83 million.
Genomic Health, Inc. sees FY2012 revenue of $230-$240 million, versus the consensus of $236.28 million.
For earnings history and earnings-related data on Genomic Health, Inc. (GHDX) click here.
Genomic Health, Inc. sees FY2012 revenue of $230-$240 million, versus the consensus of $236.28 million.
For earnings history and earnings-related data on Genomic Health, Inc. (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Optimum Communications gets NYSE non-compliance notice over stock price
- Movano (MOVE) Misses Q2 EPS by 195c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
